Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neuroblastoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

plerixafor 2Lenalidomide 2ofatumumab 1gamma-Globulins 1Trimethoprim, Sulfamethoxazole Drug Combination 1Saline Solution 1SARS-CoV-2 inactivated vaccines 1Panzyga 1Influenza Vaccines 1Immunoglobulins 1Hizentra 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Clavulanic Acid 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Agammaglobulinemia × Panzyga × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡